Showing results (241-250 of 300) with videos related to

Sort By:
Pageof 30
British Journal of Clinical Pharmacology|February 1, 1993
The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assayA F Cohen, R Kroon, H C Schoemaker, et al.
Pharmaceutical Research|January 1, 1989
Rectal absorption enhancement of des-enkephalin-gamma-endorphin (DE gamma E) by medium-chain glycerides and EDTA in conscious ratsE J van Hoogdalem, C D Heijligers-Feijen, A G de Boer, et al.
British Journal of Clinical Pharmacology|October 1, 1988
Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approachJ H Schellens, J H van der Wart, M Danhof, et al.
European Journal of Clinical Investigation|August 1, 1986
Antipyrine clearance and metabolite formation: the influence of liver volume and smokingP Spoelstra, M W Teunissen, A R Janssens, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1981
Dose-dependent stereoselectivity in the formation of mercapturic acids from cyclohexene oxide by the ratP J van Bladeren, D D Breimer, C J Seghers, et al.
Clinical Pharmacology and Therapeutics|May 1, 1994
Effects of intravenous temazepam. II. A study of the long-term reproducibility of pharmacokinetics, pharmacodynamics, and concentration-effect parametersA L van Steveninck, H C Schoemaker, J den Hartigh, et al.
Transplantation|September 1, 1985
Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipientsF C Henny, C H Kleinbloesem, A J Moolenaar, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 18, 2001
Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrierI C van der Sandt, R Smolders, L Nabulsi, et al.
Pageof 30